Wafra Investment Advisory Group Inc. NY Invests $4.86 Million in Exact Sciences Corporation (EXAS)

Wafra Investment Advisory Group Inc. NY purchased a new stake in Exact Sciences Corporation (NASDAQ:EXAS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 137,477 shares of the medical research company’s stock, valued at approximately $4,863,000. Wafra Investment Advisory Group Inc. NY owned 0.12% of Exact Sciences Corporation at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Exact Sciences Corporation in the 2nd quarter valued at about $106,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Exact Sciences Corporation by 17.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 600 shares during the period. Financial Architects Inc raised its stake in shares of Exact Sciences Corporation by 90.0% in the 2nd quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after purchasing an additional 2,035 shares during the period. Johnson Financial Group Inc. raised its stake in shares of Exact Sciences Corporation by 25.9% in the 2nd quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 1,000 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Exact Sciences Corporation by 66.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock valued at $179,000 after purchasing an additional 2,013 shares during the period. 85.22% of the stock is currently owned by hedge funds and other institutional investors.

EXAS has been the topic of several recent research reports. Vetr downgraded Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price target on the stock. in a research note on Wednesday, July 12th. BidaskClub raised Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th. Canaccord Genuity reissued a “buy” rating and issued a $45.00 price target on shares of Exact Sciences Corporation in a research note on Thursday, September 7th. Benchmark Co. set a $50.00 price target on Exact Sciences Corporation and gave the company a “buy” rating in a research note on Friday, July 7th. Finally, BTIG Research reissued a “buy” rating and issued a $45.00 price target (up previously from $35.00) on shares of Exact Sciences Corporation in a research note on Monday, July 17th. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Exact Sciences Corporation presently has a consensus rating of “Buy” and a consensus target price of $43.71.

In other news, Director Thomas D. Carey acquired 2,500 shares of Exact Sciences Corporation stock in a transaction on Thursday, August 17th. The stock was acquired at an average cost of $37.71 per share, with a total value of $94,275.00. Following the transaction, the director now owns 60,858 shares of the company’s stock, valued at approximately $2,294,955.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The disclosure for this sale can be found here. Insiders sold a total of 237,444 shares of company stock valued at $10,412,421 over the last ninety days. 4.00% of the stock is currently owned by insiders.

Exact Sciences Corporation (NASDAQ:EXAS) traded up 1.29% during trading on Tuesday, reaching $48.61. The company had a trading volume of 515,142 shares. The company’s market capitalization is $5.79 billion. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $50.65. The company has a 50-day moving average price of $43.69 and a 200 day moving average price of $35.56.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The business had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Analysts expect that Exact Sciences Corporation will post ($1.18) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Wafra Investment Advisory Group Inc. NY Invests $4.86 Million in Exact Sciences Corporation (EXAS)” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/10/10/wafra-investment-advisory-group-inc-ny-invests-4-86-million-in-exact-sciences-corporation-exas.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

What are top analysts saying about Exact Sciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exact Sciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit